Salonpas_® is the #1 Doctor Recommended Analgesic Patch ¹

Hisamitsu America announces that Salonpas has been named the number one doctor-recommended brand of pain relief patches in the United States in a survey by IQVIA.

“This recognition is meaningful because the medical community is increasingly recommending Over The Counter (OTC) topical pain relievers, and Salonpas_® has now been shown to be their first choice among topical pain relief patches”, said John Incledon, President, Hisamitsu America, the marketers of Salonpas_®, the world’s number one OTC pain patch brand.

The trend of increasing recommendations for topical pain relievers follows an expanding set of guidance and recommendations from leading medical authorities. In guidance issued in August 2020, the American College of Physicians (ACP) and the American Academy of Family Physicians (AAFP) recommend the use of topical nonsteroidal anti-inflammatory drugs (NSAIDS) as first-line therapy for treating acute, non-low back pain from musculoskeletal injuries in outpatient settings. Earlier, the Centers for Disease Control (CDC) issued guidance to clinicians to consider topical pain relievers as a first-line option in response to the Opioid crisis.

Hisamitsu America announced that Anesthesia & Research, an international, peer-reviewed scientific journal, published an exploratory pain management study, titled, "Personalized Pain Therapy: Artificial Intelligence (AI) Utilized to Predict Patient Response to OTC Topical Analgesics,” based on data from the previously published RELIEF study which studied Salonpas_® Pain Relieving Patch and found that patients treated with Salonpas_® reported greater reductions in pain severity, better quality of life outcomes, and less usage of oral pain medicines than those patients who were not treated with Salonpas_®.

"Research is core to our company principles in ensuring that we provide people in pain with safe and effective topical analgesics, and practitioners with the clinical evidence they need to confidently recommend our products for their patients," says Incledon.